

## **Multiple Myeloma: Development and clinical evaluation of a comprehensive liquid biopsy tool to monitor Minimal Residual Disease (MRD) in peripheral blood**

**Principal Investigator: Prof. Efstathios Kastritis**

### **References**

1. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. *Am J Hematol.* 2020;95:548–567.
2. Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. *Nat Rev Dis Prim.* 2017;3:1–20.
3. John L, Poos AM, Brobeil A, Schinke C, et al. Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level. *Nat Commun.* 2023 Aug 17;14(1):5011.
4. Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. *Blood Cancer J.* 2020 Sep 28;10(9):94
5. Sidana S, Tandon N, Dispenzieri A, et al. Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. *Leukemia.* 2019;33:730–738.
6. Hervé Avet-Loiseau, Valerie Lauwers-Cances, Jill Corre, PharmD, Philippe Moreau, Michel Attal NM. Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial. *Blood.* 2017;130:435.
7. Charalampous C, Kourelis T. Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications. *Front Oncol.* 2022;11:1–13.
8. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *Lancet Oncol.* 2016;17:e328–e346.
9. Anderson KC, Auclair D, Adam SJ, et al. Minimal residual disease in Myeloma: Application for clinical care and new drug registration. *Clin Cancer Res.* 2021;27:5195–5212.
10. Deshpande S, Tytarenko RG, Wang Y, et al. Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA. *Eur J Haematol.* 2021;106:230–240.
11. Mithraprabhu S, Hocking J, Ramachandran M, et al. DNA-repair gene mutations are highly prevalent in circulating tumour dna from multiple myeloma patients. *Cancers (Basel).* 2019;11:6–8.
12. Anderson KC, Auclair D, Kelloff GJ, et al. The role of minimal residual disease testing in myeloma treatment selection and drug development: Current value and future applications. *Clin Cancer Res.* 2017;23:3980–3993.
13. Lianidou E and Hoon D. Circulating Tumor Cells and circulating Tumor DNA. In: Rifai N., Horvath A.-R., Wittwer C., editors. *Tietz Textbook of Clinical Chemistry and Molecular Diagnostics.* 6th ed. Elsevier Ltd.; Amsterdam, The Netherland: 2017. pp. 1111–11.
14. Lianidou E, Pantel K. Liquid biopsies. *Genes Chromosom Cancer.* 2019;58:219–232.
15. Alix-Panabières C, Pantel K. Liquid Biopsy: From Discovery to Clinical Application. *Cancer Discov.* 2021;11:858–873.
16. Markou A, Tzanikou E, Lianidou E. The potential of liquid biopsy in the management of cancer patients. *Semin Cancer Biol.* 2022;84:69–79.
17. Ntzifa A, Lianidou E. Pre-analytical conditions and implementation of quality control steps in liquid biopsy analysis. *Crit Rev Clin Lab Sci.* 2023;0:1–22.
18. Allegra A, Cancemi G, Mirabile G, et al. Circulating Tumour Cells, Cell Free DNA and

- Tumour-Educated Platelets as Reliable Prognostic and Management Biomarkers for the Liquid Biopsy in Multiple Myeloma. *Cancers (Basel)*. 2022;14:1–19.
19. Bou Zerdan M, Kassab J, Saba L, et al. Liquid biopsies and minimal residual disease in lymphoid malignancies. *Front Oncol*. 2023;13:1–16.
  20. O'Brien A, O'Halloran F, Mykytiv V. Minimal Residual Disease in Multiple Myeloma: Potential for Blood-Based Methods to Monitor Disease. *Clin Lymphoma, Myeloma Leuk*. 2022;22:e34–e40.
  21. Sanoja-Flores L, Flores-Montero J, Garcés JJ, et al. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). *Blood Cancer J*. 2018 Nov 19;8(12):117.
  22. Garcés JJ, Bretones G, Burgos L, et al. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. *Leukemia*. 2020;34:3007–3018.
  23. Ledergor G, Weiner A, Zada M, et al. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. *Nat Med*. 2018 Dec;24(12):1867-1876.
  24. Setayesh SM, Ndacayisaba LJ, Rappard KE, et al. Targeted single-cell proteomic analysis identifies new liquid biopsy biomarkers associated with multiple myeloma. *NPJ Precis Oncol*. 2023 Sep 18;7(1):95.
  25. Terpos E, Kostopoulos I V., Papanota A-M, et al. Next Generation Flow Cytometry Provides a Standardized, Highly Sensitive and Informative Method for the Analysis of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: A Single Center Study in 182 Patients. *Blood*. 2019;134:4338–4338.
  26. Kostopoulos IV, Ntanasis-Stathopoulos I, Rousakis P, et al. Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: Prognostic and More. *J Clin Oncol*. 2023 Jan 20;41(3):708-710.
  27. Mishima Y, Paiva B, Shi J, et al. The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. *Cell Rep*. 2017;19:218–224.
  28. Ferreira B, Caetano J, Barahona F, et al. Liquid biopsies for multiple myeloma in a time of precision medicine. *J Mol Med*. 2020;98:513–525.
  29. Foulk B, Schaffer M, Gross S, et al. Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders. *Br J Haematol*. 2018;180:71–81.
  30. Garcés JJ, Cedena MT, Puig N, et al. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. *J Clin Oncol*. 2022 Sep 20;40(27):3151-3161.
  31. Chakraborty R, Lentzsch S. Circulating Tumor Cell Burden as a Component of Staging in Multiple Myeloma: Ready for Prime Time? *J Clin Oncol*. 2022;40:3099–3102.
  32. Bertamini L, Oliva S, Rota-Scalabrini D, et al. High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. *J Clin Oncol*. 2022;30:3120–3132.
  33. Termini R, Žihala D, Terpos E, et al. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma. *Clin Cancer Res*. 2022;28:4771–4781.
  34. Ntanasis-Stathopoulos I, Gavriatopoulou M, Terpos E, et al. Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis. *Clin Lymphoma, Myeloma Leuk*. 2020;20:e905–e909.
  35. Kis O, Kaedbey R, Chow S, et al. Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates. *Nat Commun*. 2017;8:1–11.
  36. Mithraprabhu S, Sirdesai S, Chen M, et al. Circulating tumour dna analysis for tumour genome characterisation and monitoring disease burden in extramedullary multiple myeloma. *Int J Mol Sci*. 2018;19:1–13.

37. Mithraprabhu S, Morley R, Khong T, et al. Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients. *Leukemia*. 2019;33:2022–2033.
38. Manzoni M, Pompa A, Fabris S, et al. Limits and applications of genomic analysis of circulating tumor DNA as a liquid biopsy in asymptomatic forms of multiple myeloma. *HemaSphere*. 2020;4:0–3.
39. Long X, Xu Q, Lou Y, et al. The utility of non-invasive liquid biopsy for mutational analysis and minimal residual disease assessment in extramedullary multiple myeloma. *Br J Haematol*. 2020;189:e45–e48.
40. Dogliotti I, Jiménez C, Varettoni M, Talaulikar D, Bagratuni T, et al. Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia. *Leukemia*. 2023 Feb;37(2):388–395.
41. Bagratuni T, Markou A, Patseas D, Mavrianou-Koutsoukou N, Aktypi F, Liacos CI, Sklirou AD, Theodorakakou F, Ntanasis-Stathopoulos I, Gavriatopoulou M, Trougakos IP, Lianidou E, Terpos E, Kastiris E, Dimopoulos MA. Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies. *Blood Adv*. 2022 Jan 11;6(1):189–199.
42. Antanasios-Stathopoulos I, Bagratuni T, Gavriatopoulou M, et al. Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations. *Am J Hematol*. 2020 Jun;95(6):E148–E150.
43. Bagratuni T, Ntanasios-Stathopoulos I, Gavriatopoulou M, et al. Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. *Leukemia*. 2018 Dec;32(12):2617–2625.
44. Markou A, Lianidou E, Georgoulas V. Metastasis-related miRNAs: A new way to differentiate patients with higher risk? *Futur Oncol*. 2015;11:365–367.
45. Markou A, Zavridou M, Lianidou ES. MiRNA-21 as a novel therapeutic target in lung cancer. *Lung Cancer Targets Ther*. 2016;7:19–27.
46. Markou A, Sourvinou I, Vorkas PA, et al. Clinical evaluation of microRNA expression profiling in non small cell lung cancer. *Lung Cancer*. 2013;81:388–396.
47. Markou A, Zavridou M, Sourvinou I, et al. Direct comparison of metastasis-related miRNAs expression levels in circulating tumor cells, corresponding plasma, and primary tumors of breast cancer patients. *Clin Chem*. 2016;62:1002–1011.
48. Giannopoulou L, Zavridou M, Kasimir-Bauer S, et al. Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes. *Transl Res*. 2019;205:77–91.
49. Sourvinou IS, Markou A, Lianidou ES. Quantification of circulating miRNAs in plasma: Effect of preanalytical and analytical parameters on their isolation and stability. *J Mol Diagnostics*. 2013;15:827–834.
50. Papanota AM, Tsiakanikas P, Kontos CK, et al. A molecular signature of circulating microRNA can predict osteolytic bone disease in multiple myeloma. *Cancers (Basel)*. 2021;13:1–17.
51. Manier S, Liu CJ, Avet-Loiseau H, Park J, Shi J, Campigotto F, Salem KZ, Huynh D, Glavey SV, Rivotto B, Sacco A, Roccaro AM, Bouyssou J, Minvielle S, Moreau P, Facon T, Leleu X, Weller E, Trippa L GI. Prognostic role of circulating exosomal miRNAs in multiple myeloma. *Blood*. 2017;129:2429–2436.
52. Zhu B, Chen H, Zhang X, et al. Serum miR-30d as a novel biomarker for multiple myeloma and its antitumor role in U266 cells through the targeting of the MTDH/PI3K/Akt signaling pathway. *Int J Oncol*. 2018;53:2131–2144.
53. Jia CM, Tian YY, Quan LN, et al. miR-26b-5p suppresses proliferation and promotes apoptosis in multiple myeloma cells by targeting JAG1. *Pathol Res Pract*.

- 2018;214:1388–1394.
54. Gupta N, Kumar R, Seth T, et al. Clinical significance of circulatory microRNA-203 in serum as novel potential diagnostic marker for multiple myeloma. *J Cancer Res Clin Oncol.* 2019;145:1601–1611.
  55. Gupta N, Kumar R, Seth T, et al. Targeting of stromal versican by miR-144/199 inhibits multiple myeloma by downregulating FAK/STAT3 signalling. *RNA Biol.* 2020;17:98–111.
  56. Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. *Proc Natl Acad Sci U S A.* 2008;105:12885–12890.
  57. Hanahan D. Hallmarks of Cancer: New Dimensions. *Cancer Discov.* 2022;12:31–46.
  58. Lianidou E. Detection and relevance of epigenetic markers on ctDNA : recent advances and future outlook. *Mol Oncol.* 2021;15:1683–1700.
  59. Heuck CJ, Mehta J, Bhagat T, et al. Myeloma Is Characterized by Stage-Specific Alterations in DNA Methylation That Occur Early during Myelomagenesis. *J Immunol.* 2013;190:2966–2975.
  60. Agnelli L, Tassone P, Neri A. Molecular profiling of multiple myeloma: From gene expression analysis to next-generation sequencing. *Expert Opin Biol Ther.* 2013;13:55–68.
  61. Agirre X, Castellano G, Pascual M, et al. Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. *Genome Res.* 2015;25:478–487.
  62. Mitchell JS, Li N, Weinhold N, et al. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. *Nat Commun.* 2016 Jul 1;7:12050.
  63. Tzanikou E et al. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study. *Mol Oncol.* 2019 Dec;13(12):2515-2530.
  64. Shen, S.Y. et al. Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA. *Nat Protoc* 14, 2749–2780 (2019).
  65. Adalsteinsson VA, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. *Nat Commun.* 2017 Nov 6;8(1):1324.
  66. Markou A et al. Highly Sensitive Detection Method of CXCR4 Tumor Hotspot Mutations by Drop-Off Droplet Digital PCR in Patients with IgM Monoclonal Gammopathies. *J Mol Diagn.* 2023 Jul;25(7):502-512.
  67. Zavidou M, et al, Development and Analytical Validation of a 6-Plex Reverse Transcription Droplet Digital PCR Assay for the Absolute Quantification of Prostate Cancer Biomarkers in Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer. *Clin Chem.* 2022; 68(10):1323-1335.
  68. Strati A, et al, Development and Analytical Validation of a Reverse Transcription Droplet Digital PCR (RT-ddPCR) Assay for PD-L1 Transcripts in Circulating Tumor Cells. *Clin Chem.* 2021;67(4):642-652.
  69. Stergiopoulou D, et al, Development and Validation of a Novel Dual-Drop-off ddPCR Assay for the Simultaneous Detection of Ten Hotspots PIK3CA Mutations. *Anal Chem.* 2023;95(37):14068-14076.
  70. Stergiopoulou D, et al, Detection of ESR1 Mutations in Primary Tumors and Plasma Cell-Free DNA in High-Grade Serous Ovarian Carcinoma Patients. *Cancers (Basel).* 2022;14(15):3790.
  71. Stergiopoulou D, et al, Development and Analytical Validation of a Highly Sensitive and Specific Blood-Based Assay for the Detection of ESR1 Mutations in Liquid Biopsies. *Cancers (Basel).* 2021;13(3):556.
  72. Tzanikou E, et al. Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients. *Clin*

- Chem Lab Med. 2020;58(11):1799-1807.
73. Ntzifa A et al. DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment. *Cancers (Basel)*. 2021 Nov 27;13(23):5974.
  74. Markou A, et al, DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early-stage NSCLC: a promising tool for early detection. *Clin Epigenetics*. 2022;14(1):61.
  75. Tserpeli V, et al, Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer. *Cancers (Basel)*. 2021 Dec 21;14(1):4.
  76. Londra D, et al, USP44 Promoter Methylation in Plasma Cell-Free DNA in Prostate Cancer. *Cancers (Basel)*. 2021 Sep 14;13(18):4607.
  77. Zavridou M, et al, Prognostic Significance of Gene Expression and DNA Methylation Markers in Circulating Tumor Cells and Paired Plasma Derived Exosomes in Metastatic Castration Resistant Prostate Cancer. *Cancers (Basel)*. 2021 Feb 13;13(4):780.
  78. Mastoraki S, et al, KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer. *Mol Oncol*. 2021 Sep;15(9):2412-2422.
  79. Zavridou M, et al, Direct comparison of size-dependent versus EpCAM-dependent CTC enrichment at the gene expression and DNA methylation level in head and neck squamous cell carcinoma. *Sci Rep*. 2020 Apr 16;10(1):6551.
  80. Zavridou M, et al, Evaluation of Preanalytical Conditions and Implementation of Quality Control Steps for Reliable Gene Expression and DNA Methylation Analyses in Liquid Biopsies. *Clin Chem*. 2018 Oct;64(10):1522-1533.